Manager TitleAgeSince
Chief Executive Officer 53 01/01/2011
Director of Finance/CFO 47 01/11/2010
Chief Tech/Sci/R&D Officer - 15/03/2022
Director TitleAgeSince
Chairman 53 01/06/2014
Chairman 66 26/07/2019
Director/Board Member 67 18/02/2021
Change 5-day change 1-year change 3-year change Capi.($)
-14.27%-76.47% - - 1.7M
-1.34%-3.09%+56.10%+68.83% 65.45B
-0.12%-3.16%+7.67%+90.50% 58.93B
+0.71%+0.78%+26.74%+87.91% 55.21B
-2.34%-3.90%+10.90%+115.97% 46.1B
+0.09%-6.08%+18.67%+25.90% 42.49B
-2.58%+0.24%+18.54%+41.28% 35.56B
-1.76%-11.56%+126.44%+649.27% 34.57B
+0.89%-0.48%+77.51%+58.24% 32.46B
-1.69%-0.79%-40.58%+382.68% 26.28B
Average -2.24%-3.40%+33.55%+168.95% 44B
Weighted average by Cap. -0.82%-3.29%+33.69%+143.55%
Logo ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
Employees
35
  1. Stock Market
  2. Stocks
  3. ASLN Stock